Ultimovacs Overview
- Founded
- 2011
- Status
- Public
- Employees
- 21
- Stock Symbol
- ULTI
- Investments
- 1
- Share Price
- $8.42
- (As of Thursday Closing)
Ultimovacs General Information
Description
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
OSL
Primary Office
- Ullernchausséen 64
- 0379 Oslo
- Norway
+47 413 00 000
Ultimovacs Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.42 | $8.18 | $3.70 - $10.66 | $270M | 32M | 23.8K | -$0.42 |
Ultimovacs Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2020 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
|---|---|---|---|---|
| EV | 251,846 | 251,846 | 78,800 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (12,911) | (12,911) | (7,313) | (6,852) |
| Net Income | (12,740) | (12,740) | (6,948) | (6,788) |
| Total Assets | 62,051 | 62,051 | 54,203 | 21,792 |
| Total Debt | 443 | 443 | 411 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ultimovacs Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Ultimovacs‘s full profile, request access.
Request a free trialUltimovacs Executive Team (9)
Ultimovacs Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 00000000 000000 | Self | Board Member | 000 0000 |
| 00ø00 00000000 | Gjelsten Holding | Board Member | 000 0000 |
| 000000 000ü00000 | Gjelsten Holding | Board Member | 000 0000 |
| 00000 000000000 00 | Self | Board Member | 000 0000 |
| 00000 0000000000 | Self | Director | 000 0000 |
Ultimovacs Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialUltimovacs Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 03-Sep-2018 | 0000000000 | 00.000 | Drug Discovery | 0000 0000000 00.0 |
Ultimovacs Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000000 | Drug Discovery | Uppsala, Sweden | 0000 |